Classification Term: 625

Pyridinylpyrimidines (ontology term: CHEMONTID:0000342)

Compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond." []

found 7 associated metabolites at category metabolite taxonomy ontology rank level.

Ancestor: Pyrimidines and pyrimidine derivatives

Child Taxonomies: There is no child term of current ontology term.

AFN911

N-[4-(hydroxymethyl)-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}cyclohexa-1,5-dien-1-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide

C29H33N7O2 (511.2695598)


AFN911 is a cytochrome P450 (CYP2D6) metabolite of Imatinib. Imatinib is a tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia (CML) with BCR-ABL activity, gastrointestinal stromal tumors and acute lymphocytic leukemia (ALL). AFN911 is a 2-phenyl amino pyrimidine derivative. AFN911 is only found in individuals who have consumed or received the drug Imatinib.

   

N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine

6-methyl-N1-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine

C16H15N5 (277.132739)


   

Buparlisib

5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)-1,2-dihydropyridin-2-imine

C18H21F3N6O2 (410.1678002)


C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor

   

Avosentan

5-Methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide

C23H21N5O5S (479.12633360000007)


C28313 - Endothelin Receptor Antagonist Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist. IC50 value: Target: ETA receptor

   

Clazosentan

N-[6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-1,2,3,4-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methylpyridine-2-sulphonamide

C25H23N9O6S (577.1491938)


C28313 - Endothelin Receptor Antagonist Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction[1][5].

   

Ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate

Ethyl 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid

C24H27N5O2 (417.2164642)


   

Tezosentan

N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-1,2,3,4-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-(propan-2-yl)pyridine-2-sulfonamide

C27H27N9O6S (605.1804922000001)


D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents C28313 - Endothelin Receptor Antagonist